Biomarkers of Renal Cancer

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Sex

All

Minimum age

18 Years

Inclusion Criteria for renal-mass patients:

* Men and women over 18 years of age
* Diagnosis of first episode of renal mass
* Caucasian race
* Signed, informed consent

Exclusion Criteria renal-mass patients:

* Any other concomitant cancer or history of active cancer in the last 5 years
* Oncological genetic syndrome
* Previous history of renal tumour
* Urothelial cancer
* End-stage renal disease on hemodialysis
* Bilateral renal cell carcinoma

Inclusion Criteria for control subjects:

* Men and women over 18 years of age
* Caucasian race
* Living kidney donor or patient with urological functional diseases (e.g. kidney stones, benign prostate hypertrophy, etc..)
* Signed, informed consent

Exclusion criteria for control subjects:

* History of active cancer in the last 5 years
* Oncological genetic syndrome
* End-stage renal disease on hemodialysis or peritoneal dialysis

• BACKGROUNDCapitanio U, Terrone C, Antonelli A, Minervini A, Volpe A, Furlan M, Matloob R, Regis F, Fiori C, Porpiglia F, Di Trapani E, Zacchero M, Serni S, Salonia A, Carini M, Simeone C, Montorsi F, Bertini R. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol. 2015 Apr;67(4):683-9. doi: 10.1016/j.eururo.2014.09.027. Epub 2014 Oct 3. PMID 25282367
• BACKGROUNDChanudet E, Wozniak MB, Bouaoun L, Byrnes G, Mukeriya A, Zaridze D, Brennan P, Muller DC, Scelo G. Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease. Int J Cancer. 2017 Nov 1;141(9):1730-1740. doi: 10.1002/ijc.30845. Epub 2017 Jul 7. PMID 28639257
• BACKGROUNDChow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010 May;7(5):245-57. doi: 10.1038/nrurol.2010.46. PMID 20448658
• BACKGROUNDCumberbatch MG, Rota M, Catto JW, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2016 Sep;70(3):458-66. doi: 10.1016/j.eururo.2015.06.042. Epub 2015 Jul 3. PMID 26149669
• BACKGROUNDFedorko M, Stanik M, Iliev R, Redova-Lojova M, Machackova T, Svoboda M, Pacik D, Dolezel J, Slaby O. Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma. Int J Mol Sci. 2015 Sep 29;16(10):23382-9. doi: 10.3390/ijms161023382. PMID 26426010
• BACKGROUNDGatto F, Maruzzo M, Magro C, Basso U, Nielsen J. Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. Front Oncol. 2016 Nov 24;6:253. doi: 10.3389/fonc.2016.00253. eCollection 2016. PMID 27933273